Announces the Intention to Grant a Patent Vancouver, British Columbia--(Newsfile Corp. - November 2, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC Pink: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce the intention to grant a patent.
CVR Medical is pleased to announce that it has received a Communication under Rule 71(3) from the European Patent Office (the "EPO") for its Sensor, Sensor Pad and Sensor Array for Detecting Infrasonic Acoustic Signals informing CVR of the intention to grant a patent based on the prosecuted application. This is the first allowed patent application for CVR Medical at the EPO and an integral part of the CVR IP portfolio with an early priority date of June 24, 2010. The application, which was prosecuted under application no. 11754558.2 is directed to a sensor, sensor pad and sensor array for detecting infrasonic signals in a living organism and can be used for detecting levels of stenosis, occlusion, or aneurysm in arteries. CVR Medical will issue an update on Patents and clinical developments as we move forward.
About CVR Medical
CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device ("CSS"). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical's shares are listed on the OTCQX under the symbol "CRRVF". The Company is listed for trading under the symbol "CVM". Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com.
https://www.newsfilecorp.com/release/101692
